Advertisement

International Journal of Clinical Oncology

, Volume 14, Issue 4, pp 326–331 | Cite as

Factors correlated with peritoneal carcinomatosis and survival in patients with gastric cancer treated at a single institution in Brazil

  • Marcello F. Fanelli
  • Milton J. B. Silva
  • Tadeu F. de PaivaJr
  • Ludmilla T. D. Chinen
  • Andréa P. G. Guimarães
  • Daniel L. Gimenes
  • Edilson D. Pinheiro
  • José A. RinckJr
  • Ulisses R. Nicolau
  • Solange M. Sanches
  • Celso A. L. Melo
  • Aldo L. A. Dettino
  • Marcelo R. S. Cruz
  • Leila Maria M. P. de Melo
  • Maria N. C. Formiga
  • Vladmir C. C. de Lima
Original Article

Abstract

Background

Gastric cancer is the second leading cause of death due to cancer worldwide and is particularly prevalent in Brazil. Promising new therapeutic agents have already shown activity in some gastrointestinal malignancies and their role in gastric cancer will need to be evaluated. Determining the prognostic factors of survival for patients with gastric cancer can help in identifying patients with a worse prognosis after treatment with the current chemotherapeutic regimens.

Methods

A retrospective chart review of 186 patients diagnosed with gastric cancer and treated at a single institution in Brazil from January 1994 to December 2004 was carried out. Univariate and multivariate analyses were performed to identify patient- and tumor-related characteristics associated with peritoneal metastasis at diagnosis and with overall survival.

Results

Of the 186 patients, 76 were alive at the time of this analysis. The median survival for all patients was 30.1 months. Two independent factors associated with the presence of peritoneal metastasis at diagnosis were identified by multivariate analysis: signet-ring cell type (odds ratio [OR], 10.8; 95% confidence interval [CI], 3.1 to 37.5), and visceral metastasis (OR, 51.8; 95% CI, 12.4 to 215.4). The prognostic factors for poor survival were tumor stage T3 or T4 (hazard ratio [HR], 1.87; 95% CI, 1.09 to 3.22) and visceral metastasis (HR, 4.98; 95% CI, 3.02 to 8.20).

Conclusion

Two factors correlated with peritoneal metastasis and two prognostic factors for survival were identified. These findings may contribute to clinical decision-making, treatment tailoring, and the design of future trials.

Key words

Multivariate analysis Neoplasm metastasis Peritoneum Prognosis Stomach neoplasms Survival analysis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Kamangar F, Dores GM, Anderson WF (2006) Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24:2137–2150PubMedCrossRefGoogle Scholar
  2. 2.
    Curtis RE, Kennedy BJ, Myers MH, et al. (1985) Evaluation of AJC stomach cancer staging using the SEER population. Semin Oncol 12:21–31PubMedGoogle Scholar
  3. 3.
    Levi F, Lucchini F, Gonzalez JR, et al. (2004) Monitoring falls in gastric cancer mortality in Europe. Ann Oncol 15:338–345PubMedCrossRefGoogle Scholar
  4. 4.
    Levi F, Lucchini F, Negri E, et al. (2004) Cancer mortality in Europe, 1995–1999, and an overview of trends since 1960. Int J Cancer 110:155–169PubMedCrossRefGoogle Scholar
  5. 5.
    Parkin DM (2001) Global cancer statistics in the year 2000. Lancet Oncol 2:533–543PubMedCrossRefGoogle Scholar
  6. 6.
    Curado MP, Edwards B, Shin HR, et al. (eds) (2007) Cancer incidence in five continents, vol. IX. IARC Scientific Publications No. 160, LyonGoogle Scholar
  7. 7.
    Roukos DH, Kappas AM (2005) Perspectives in the treatment of gastric cancer. Nat Clin Pract Oncol 2:98–107PubMedCrossRefGoogle Scholar
  8. 8.
    Tsubono Y, Hisamichi S (2000) Screening for gastric cancer in Japan. Gastric Cancer 3:9–18PubMedCrossRefGoogle Scholar
  9. 9.
    Hurwitz H, Fehrenbacher L, Novotny W, et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342PubMedCrossRefGoogle Scholar
  10. 10.
    Cunningham D, Humblet Y, Siena S, et al. (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351: 337–345PubMedCrossRefGoogle Scholar
  11. 11.
    Demetri GD, van Oosterom AT, Garrett CR, et al. (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368:1329–1338PubMedCrossRefGoogle Scholar
  12. 12.
    Demetri GD, von Mehren M, Blanke CD, et al. (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472–480PubMedCrossRefGoogle Scholar
  13. 13.
    Anonymous (1993) A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. N Engl J Med 329:987–994Google Scholar
  14. 14.
    Cheng SH, Horng CF, Clarke JL, et al. (2006) Prognostic index score and clinical prediction model of local regional recurrence after mastectomy in breast cancer patients. Int J Radiat Oncol Biol Phys 64:1401–1409PubMedGoogle Scholar
  15. 15.
    Weigelt B, Peterse JL, van’t Veer LJ (2005) Breast cancer metastasis: markers and models. Nat Rev Cancer 5:591–602PubMedCrossRefGoogle Scholar
  16. 16.
    Thompson IM, Ankerst DP, Chi C, et al. (2006) Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 98:529–534PubMedCrossRefGoogle Scholar
  17. 17.
    Greipp PR, San Miguel J, Durie BG, et al. (2005) International staging system for multiple myeloma. J Clin Oncol 23:3412–3420PubMedCrossRefGoogle Scholar
  18. 18.
    Motzer RJ, Mazumdar M, Bacik J, et al. (1999) Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17:2530–2540PubMedGoogle Scholar
  19. 19.
    Bedikian AY, Chen TT, Khankhanian N, et al. (1984) The natural history of gastric cancer and prognostic factors influencing survival. J Clin Oncol 2:305–310PubMedGoogle Scholar
  20. 20.
    Chau I, Norman AR, Cunningham D, et al. (2004) Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer-pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol 22:2395–2403PubMedCrossRefGoogle Scholar
  21. 21.
    Yao JC, Tseng JF, Worah S, et al. (2005) Clinicopathologic behavior of gastric adenocarcinoma in Hispanic patients: analysis of a single institution’s experience over 15 years. J Clin Oncol 23:3094–3103PubMedCrossRefGoogle Scholar
  22. 22.
    Rohatgi PR, Yao JC, Hess K, et al. (2006) Outcome of gastric cancer patients after successful gastrectomy: influence of the type of recurrence and histology on survival. Cancer 107:2576–2580PubMedCrossRefGoogle Scholar
  23. 23.
    Patel PR, Yao JC, Hess K, et al. (2007) Effect of timing of metastasis/disease recurrence and histologic differentiation on survival of patients with advanced gastric cancer. Cancer 110:2186–2190PubMedCrossRefGoogle Scholar
  24. 24.
    American Joint Committee on Cancer AJCC Cancer staging manual, 6th edn. Lippincott Williams & Wilkins, PhiladelphiaGoogle Scholar
  25. 25.
    Kim JP, Lee JH, Kim SJ, et al. (1998) Clinicopathologic characteristics and prognostic factors in 10 783 patients with gastric cancer. Gastric Cancer 1:125–133PubMedCrossRefGoogle Scholar
  26. 26.
    Barchielli A, Amorosi A, Balzi D, et al. (2001) Long-term prognosis of gastric cancer in a European country: a population-based study in Florence (Italy). Ten-year survival of cases diagnosed in 1985–1987. Eur J Cancer 37:1674–1680PubMedCrossRefGoogle Scholar
  27. 27.
    Costa ML, de Cassia Braga Ribeiro K, Machado MA, et al. (2006) Prognostic score in gastric cancer: the importance of a conjoint analysis of clinical, pathologic, and therapeutic factors. Ann Surg Oncol 13:843–850PubMedCrossRefGoogle Scholar
  28. 28.
    Alici S, Kaya S, Izmirli M, et al. (2006) Analysis of survival factors in patients with advanced-stage gastric adenocarcinoma. Med Sci Monit 12:CR221–229PubMedGoogle Scholar
  29. 29.
    Lai JF, Kim S, Li C, et al. (2008) Clinicopathologic characteristics and prognosis for young gastric adenocarcinoma patients after curative resection. Ann Surg Oncol 15:1464–1469PubMedCrossRefGoogle Scholar
  30. 30.
    Santoro R, Carboni F, Lepiane P, et al. (2007) Clinicopathological features and prognosis of gastric cancer in young European adults. Br J Surg 94:737–742PubMedCrossRefGoogle Scholar
  31. 31.
    Lazo G, Yao JC, Najam AA, et al. (2002) Clinical risk factors for peritoneal metastases in esophagogastric junction carcinoma (GEJC). Proc Am Soc Clin Oncol 21; abstract 562Google Scholar
  32. 32.
    Li C, Kim S, Lai JF, et al. (2007) Advanced gastric carcinoma with signet ring cell histology. Oncology 72:64–68PubMedCrossRefGoogle Scholar
  33. 33.
    Harrison JD, Fielding JW (1995) Prognostic factors for gastric cancer influencing clinical practice. World J Surg 19:496–500PubMedCrossRefGoogle Scholar
  34. 34.
    Abe S, Ogawa Y, Nagasue N, et al. (1984) Early gastric cancer: results in a general hospital in Japan. World J Surg 8:308–314PubMedCrossRefGoogle Scholar
  35. 35.
    Nagata T, Ikeda M, Nakayama F (1983) Changing state of gastric cancer in Japan. Histologic perspective of the past 76 years. Am J Surg 145:226–233PubMedCrossRefGoogle Scholar
  36. 36.
    Kim JG, Ryoo BY, Park YH, et al. (2008) Prognostic factors for survival of patients with advanced gastric cancer treated with cisplatin-based chemotherapy. Cancer Chemother Pharmacol 61:301–307PubMedCrossRefGoogle Scholar
  37. 37.
    Yoshida M, Ohtsu A, Boku N, et al. (2004) Long-term survival and prognostic factors in patients with metastatic gastric cancers treated with chemotherapy in the Japan Clinical Oncology Group (JCOG) study. Jpn J Clin Oncol 34:654–659PubMedCrossRefGoogle Scholar
  38. 38.
    Lee J, Lim T, Uhm JE, et al. (2007) Prognostic model to predict survival following first-line chemotherapy in patients with metastatic gastric adenocarcinoma. Ann Oncol 18:886–891PubMedCrossRefGoogle Scholar

Copyright information

© Japan Society of Clinical Oncology 2009

Authors and Affiliations

  • Marcello F. Fanelli
    • 1
  • Milton J. B. Silva
    • 1
  • Tadeu F. de PaivaJr
    • 1
  • Ludmilla T. D. Chinen
    • 1
  • Andréa P. G. Guimarães
    • 1
  • Daniel L. Gimenes
    • 1
  • Edilson D. Pinheiro
    • 1
  • José A. RinckJr
    • 1
  • Ulisses R. Nicolau
    • 1
  • Solange M. Sanches
    • 1
  • Celso A. L. Melo
    • 1
  • Aldo L. A. Dettino
    • 1
  • Marcelo R. S. Cruz
    • 1
  • Leila Maria M. P. de Melo
    • 1
  • Maria N. C. Formiga
    • 1
  • Vladmir C. C. de Lima
    • 1
  1. 1.Fundação Antônio PrudenteHospital do Câncer A.C. CamargoLiberdade, São PauloBrazil

Personalised recommendations